Brand companies identified in CPS or whether generic versions are available

Size: px
Start display at page:

Download "Brand companies identified in CPS or whether generic versions are available"

Transcription

1 Appendix 3: Guideline-level data on recommended drugs and guideline-affiliated organizations Clinical practice guideline ID # Most recent review or publish date CPS year Clinical practice guideline title The Hypertension Education Program (CHEP) Guidelines for Pharmacists: An Update Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) Collaborative Update of CANMAT Guidelines for the Patients with Bipolar Disorder: 2009 Small Cell Carcinoma of the Bladder: Consensus Guidelines from the Association of Genitourinary Medical Oncologists (CAGMO) Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) Collaborative Drugs recommended for first-line treatment Brand companies identified in CPS or whether generic versions are available Name of recommended drug identified in CPS or brand name to which generic name redirects Guidelineaffiliated organizations and [source] of identified relationship with pharmaceutical companies spironolactone EPICORE Centre/ COMPRIS [1] eplerenone Pfizer Inspira lithium Network for Mood and divalproex Anxiety olanzapine Treatments (CANMAT) risperidone [2] quetiapine International quetiapine XR Society for Bipolar aripiprazole Bristol-Myers Squibb Abilify Disorders (ISBD) [3] ziprasidone Pfizer Zeldox lamotrigine bupropion cisplatin Association of carboplatin Medical etoposide Oncologists (CAMO) [4] irinotecan lithium Network for Mood and divalproex Anxiety divalproex ER Treatments (CANMAT) olanzapine [2] risperidone Identified pharmaceutical companies with relationship with organizations 1 - Apotex Inc. - AstraZeneca Canada - Bayer Healthcare - Bristol-Myers Squibb/Sanofi- Aventis - Merck Frosst Canada CANMAT ISBD - Janssen Pharmaceutical Companies - Forest - Teva Pharmaceutical Industries - Sunovion 1 Excludes corporate sponsorship of conferences.

2 Update of CANMAT Guidelines for the Patients with Bipolar Disorder: Update 2013 quetiapine quetiapine XR aripiprazole Bristol-Myers Squibb Abilify ziprasidone Pfizer Zeldox asenapine Merck Saphris paliperidone ER Janssen Invega lamotrigine The 2012 Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure bupropion furosemide nitroglycerin Society (CCS) nesiritide Janssen Natrecor [5 7] nitroprusside Hospira Nipride tolvaptan Otsuka Samsca eplerenone Pfizer Inspra spironolactone metolazone Sanofi-Aventis Zaroxolyn digoxin - AstraZeneca Canada Inc. - PendoPharm - Servier Canada Inc. - Bristol Myers Squibb - Bayer - Boehringer Ingelheim - Merck - Amgen isosorbide dinitrate hydralazine Bortezomib in Multiple Myeloma and Lymphoma Recommendations for Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation CUA-CUOG Guidelines for the Aspirin bortezomib Janssen Velcade Cancer Care Ontario (CCO) melphalan Triton Pharma Alkeran [8,9] prednisone dexamethasone Peginterferon, Pegasys, pegylated liposomal Pegasys RBV (Pegasys Roche, Merck doxorubicin and Copegus), Pegetron, Unitron PEG acetylsalicylic acid Agency for Drugs and clopidogrel Technologies in warfarin Health (CADTH) [10] dabigatran Boehringer-Ingelheim Pradax rivaroxaban Bayer Xarelto apixaban Bristol-Myers Squibb Eliquis abiraterone acetate Janssen Zytiga prednisone - Astellas - Actavis

3 Castration-Resistant Prostate Cancer (CRPC): 2013 Update docetaxel Hospira Taxotere Urological Association (CUA) cabazitaxel Sanofi-Aventis Jevtana [11] enzalutamide Astellas Xtandi denosumab Amgen Prolia, Xgeva zolendronic acid calcium Novartis Aclasta, Zometa concentrate - GlaxoSmithKline Advanced Kidney Cancer: Kidney Cancer Forum 2013 Consensus Update Telestroke Action Collaborate Telestroke Implementation Toolkit October 2013 vitamin D high-dose interleukin-2 (HD IL- 2) Novartis pazopanib GlaxoSmithKline Votrient tivozanib Proleukin, aldesleukin not found in CPS or DPD temsirolimus Pfizer Torisel bevacizumab Roche Avastin everolimus Novartis Afinitor sorafenib Bayer Nexavar sunitinib Pfizer Sutent insulin NPH Eli Lilly, NovoNordisk Humulin-N, Novolinge NPH alteplase (tpa) Roche Activase rtpa, Cathflo Kidney Cancer Research Network of Canada,[12] Kidney Cancer Canada [13] Heart and Stroke Foundation [14] Kidney Cancer Research Network of Canada: - Password protected Kidney Cancer Canada - Astellas Pharma Canada - AstraZeneca - Bayer Inc. - Boehringer Ingelheim Canada - Rx&D - Celgene Canada - Eli Lilly & Co. - GlaxoSmithKline - Janssen - Novartis - Roche - Bayer Inc. - Boehringer Ingelheim - Bristol-Myers Squibb - Janssen - Allergan - Merz Headache Society Guideline Acute Drug Therapy for Migraine Headache acetaminophen Headache Network Canada McNeil Consumer almotriptan Axert [15] Healthcare acetylsalicylic acid diclofenac potassium dihydroergotamine eletriptan Pfizer Relpax ergotamine frovatriptan Novartis Cafergot ibuprofen metoclopramide

4 naproxen sodium naratriptan rizatriptan Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation The Use of Antiviral Drugs for Influenza: Guidance for Practitioners 2012/2013 Focused 2012 Update of the Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control sumatriptan zolmitriptan domperidone codeine tramadol warfarin oseltamivir (Tamiflu "by Hoffman-La Roche Ltd, Canada)" zanamivir Roche GlaxoSmithKline Relenza Society (CCS) [5 7] Association of Medical Microbiology and Infectious Disease Canada [16] acetylsalicylic acid dabigatran Boehringer-Ingelheim Pradax rivaroxaban Bayer Xarelto apixaban Bristol-Myers Squibb Eliquis clopidogrel Sanofi-Aventis Plavix diltiazem verapamil digoxin dronedarone Sanofi-Aventis Multaq flecainide Graceway Tambocor propafenone sotalol Propafenone (Sanis Sanis Health, Abbott Health); Rythmol (Abbott) Society (CCS) [5 7] - AstraZeneca Canada Inc. - PendoPharm - Servier Canada Inc. - Bristol Myers Squibb - Bayer - Boehringer Ingelheim - Merck - Amgen - AstraZeneca Canada Inc. - PendoPharm - Servier Canada Inc. - Bristol Myers Squibb - Bayer - Boehringer Ingelheim - Merck - Amgen Patients with Refractory Angina: amiodarone allopurinol ranolazine not found in CPS or DPD Society (CCS) trimetazidine not found in CPS or DPD [5 7] - AstraZeneca Canada Inc. - PendoPharm - Servier Canada Inc.

5 Society/ Pain Society Joint Guidelines Ophthalmological Society Evidence- Based Clinical Practice Guidelines for the Management of Diabetic Retinopathy Managing Cardiometabolic Risk in Primary Care nicorandil not found in CPS or DPD - Bristol Myers Squibb - Bayer - Boehringer Ingelheim ivabradine not found in CPS or DPD - Merck ranibizumab Novartis Lucentis Ophthalmological Society [17,18] - Amgen metformin None clearly - n/a bupropion identified varenicline Pfizer Champix EMLA Cream Pain (AstraZeneca); EMLA Society (CPS) Patch (AstraZeneca); [19] Lidocaine Parenteral - Evidence-Based Antiarrhythmic Agent Guideline for (Hospira); Lidodan Neuropathic Pain Endotracheal (Odan); Interventional Lidodan Viscous Treatments: Spinal AstraZeneca, Hospira, (Odan); Xylocaine Jelly lidocaine Cord Stimulation, Odan 2% (AstraZeneca); Intravenous Xylocaine Parenteral Infusions, Epidural Without Epinepherine Injections, and Nerve (AstraZeneca); Blocks Xylocaine Topical 4% (AstraZeneca); Xylocaine Viscous 2% (AstraZeneca); Xylocard (AstraZeneca) Lenalidomide in lenalidomide Celgene Revlimid Cancer Care

6 Multiple Myeloma dexamethasone Alcon, Sanofi-Aventis dexamethasone/ciproflo xacin HCl = Ciprodex (Alcon); dexamethasone/framyce tin sulfate/gramicidin = Sofracort (Sanofi- Aventis); dexamethasone/neomyc in sulfate/polumixin B sulfate = Maxitrol (Alcon); dexamethasone/tobramy cin = Tobradex (Alcon) Ontario (CCO) [8,9] Risk Reduction of Prostate Cancer with Drugs or Nutritional Supplements The 2012 Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy acetylsalicylic acid enoxaparin Sanofi-Aventis Lovenox; Lovenox HP granulocyte-colony stimulating factor (GCSF) Amgen Neupogen (filgrastim) finasteride Cancer Care Ontario (CCO) dutasteride GlaxoSmithKline Avodart [8,9] acetylsalicylic acid Hypertension Canada,[20] Pharmacy Association,[21] Council of Nurses,[22] Heart and Stroke Foundation of Canada[14] Hypertension Canada - Servier - Abbott - Merck Pharmacy Association Council of Nurses - AstraZeneca Heart and Stroke Foundation - Bayer Inc. - Boehringer Ingelheim - Bristol-Myers Squibb - Janssen - Allergan - Merz New Oral dabigatran Boehringer-Ingelheim Pradax Agency

7 Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation The Role of Liver Resection in Colorectal Cancer Metastases Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma Rheumatology Association Recommendations for the Pharmacological Rheumatoid Arthritis with Traditional and Biologic Diseasemodifying Antirheumatic Drugs: Part II Safety rivaroxaban Bayer Xarelto for Drugs and Technologies in Health (CADTH) [10] oxaliplatin Sanofi-Aventis Eloxatin Cancer Care Ontario (CCO) irinotecan Pfizer Camptosar [8,9] doxorubicin Janssen Caelyx Cancer Care Ontario (CCO) Gemcitabine [8,9] Docetaxel Hospira, Sanofi-Aventis docetaxel, Taxotere granulocyte-colony stimulating factor (GCSF) methotrexate Amgen Hospira, Pfizer, Medexus abatacept Bristol-Myers Squibb Orencia tocilizumab Roche Actemra influenza vaccine pneumococcal vaccine hepatitis B vaccine herpes zoster vaccine Abbott, Sanofi-Pasteur, Novartis, AstraZeneca Sanofi-Pasteur, Merck, Pfizer, GlaxoSmithKline GlaxoSmithKline, Merck not found - unspecific Neupogen (filgrastim) Methotrexate, Methotrexate injection, Methotrexate tablets, Metoject FluMist, Intanza, Agriflu, Influvac, Fluad Pneumo 23, Prevnar 13, Synflorix, Pneumovax 23 Energix-B, Recombivax HB Rheumatology Association [23] - Abbvie Corporation Canada - Amgen Canada Inc. - Celgene Inc. - Janssen Inc. - Roche Canada - Bristol-Myers Squibb Canada Co. - GlaxoSmithKline Inc. - Hospira - UCB Canada Inc. - AstraZeneca Canada Inc. - Eli Lilly Canada Inc. hydroxychloroquine Sanofi-Aventis Plaquenil sulfasalazine Neonatal Abstinence Syndrome Clinical Practice Guidelines for Ontario rituximab Roche Rituxan methadone Paladin Metadol None clearly identified Purdue Pharma, RB Suboxone, BuTrans5, buprenorphine BuTrans10, BuTrans20 morphine - n/a

8 Chronic Hepatitis B: Association for the Study of the Liver Consensus Guidelines hepatitis B vaccine PEG IFN tenofovir GlaxoSmithKline, Merck Roche, Merck Gilead Sciences Energix-B, Recombivax HB Peginterferon, Pegasys, Pegasys RBV (Pegasys and Copegus), Pegetron, Unitron PEG Viread, Atripla, Truvada entecavir Bristol-Myers Squibb Baraclude lamivudine ViiV Healthcare Shire Canada 3TC, Heptovir, Kivexa, Trizivir, Combivir Liver Foundation [24] - Abbvie - Astellas - Bayer HealthCare - Bristol-Myers Squibb - Gilead Sciences - Janssen - BTG - Merck - Vertex Recommendations of the 4 th Consensus Conference on the Diagnosis and Treatment of Dementia emtricitabine Gilead Sciences Atripla, Truvada hepatitis immune Talecris HyperHEP B SD globulin risperidone Institutes olanzapine of Health Research, Fonds de la recherche en santé du Québec, Alzheimer Society of Canada, Consortium of Centres for Clinical Cognitive Research, Neurological Society, Academy of Geriatric aripiprazole Bristol-Myers Squibb Abilify Psychiatry, Quebec Network for Research on Aging, and Geriatrics Society [25 33] Institutes of Health Research Fonds de la recherche en santé du Québec - AllerGen NCE Inc. - Merck Sharp & Dohme Canada Inc. Alzheimer Society of Canada - Rx&D Consortium of Centres for Clinical Cognitive Research Neurological Society - Biogen Idec - MS - Novartis - Biocodex - Allergan - Eisai - Grifols - UCB - Teva - EMD Serono - Sunovion - Genzyme Academy of Geriatric

9 Psychiatry Quebec Network for Research on Aging Geriatrics Society

10 References 1. EPICORE Centre Epidemiology Coordinating and Research Centre. Sponsors and Collaborators [Internet] [cited 2015 Apr 10]. Available from: 2. Network for Mood and Anxiety Treatments (CANMAT). Welcome to CANMAT [Internet] [cited 2015 May 15]. Available from: 3. International Society for Bipolar Disorders (ISBD). Fiscal 2012 Annual Report [Internet] [cited 2015 May 15]. Available from: 4. Association of Medical Oncologists (CAMO). Home Page [Internet] [cited 2015 May 7]. Available from: 5. Society (CCS). CCSA Donations: October 1, 2013-September 30, 2014 [Internet] [cited 2015 May 7]. Available from: 6. Society (CCS). Recognizing our Donors [Internet] [cited 2015 May 7]. Available from: 7. Society (CCS). Guideline Resources [Internet] [cited 2015 May 15]. Available from: 8. Cancer Care Ontario (CCO). Financial Statements [Internet] Available from: 9. Cancer Care Ontario (CCO). Cancer Care Ontario Financial Statements [Internet] Available from: Association for Drugs and Technologies in Health (CADTH). Sponsors and Exhibitors [Internet] [cited 2015 May 7]. Available from: Urological Association (CUA). Homepage [Internet] [cited 2015 May 7]. Available from: Kidney Cancer Research Network of Canada (KCRNC). Our Supporters [Internet] [cited 2015 May 7]. Available from:

11 13. Kidney Cancer Canada (KCC). Our Partners and Sponsors [Internet] [cited 2015 May 7]. Available from: Heart and Stroke Foundation. Our National Corporate Sponsors [Internet] [cited 2015 May 7]. Available from: orporate_partners.htm 15. Headache Network Canada (HNC). Home [Internet] [cited 2015 May 7]. Available from: Association of Medical Microbiology and Infectious Disease Canada. Home [Internet] [cited 2015 May 7]. Available from: Ophthalmological Society (COS). COS Affiliates [Internet] [cited 2015 May 7]. Available from: Ophthalmological Society (COS). Partners & Supporters [Internet] [cited 2015 May 7]. Available from: Pain Society (CPS). Home [Internet] [cited 2015 May 7]. Available from: Hypertension Canada. Supporters and Corporate Partners [Internet] [cited 2015 May 7]. Available from: Pharmacists Association (CPA). Partnerships [Internet] [cited 2015 May 7]. Available from: Council for Nurses (CCCN). Sponsors [Internet] [cited 2015 May 1]. Available from: Rheumatology Association (CRA). Sponsors and Exhibitors [Internet] [cited 2015 May 7]. Available from: Liver Foundation. National Partners & Sponsors [Internet] [cited 2015 May 7]. Available from: Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD) Consensus Conference on Dementia [Internet] [cited 2015 May 7]. Available from:

12 26. Institute for Health Information (CIHI). About CIHI [Internet] [cited 2015 May 7]. Available from: Fonds de la recherche en santé du Québec. Nos Partenaires [Internet]. Wall Street Journal [cited 2015 May 2]. Available from: Alzheimer Society of Canada. Our Partners [Internet] [cited 2015 May 7]. Available from: Consortium of Centres for Clinical Cognitive Research (C5R). About [Internet] [cited 2015 May 7]. Available from: Neurological Sciences Federation. Our Generous Sponsors [Internet] [cited 2015 May 7]. Available from: Academy of Geriatric Psychiatry (CAGP). About CAGP [Internet] [cited 2015 May 7]. Available from: Quebec Network for Research on Aging. Partners [Internet] [cited 2015 May 7]. Available from: Geriatrics Society. Donor Recognition Wall [Internet] [cited 2015 May 7]. Available from: _wall.pdf

A Clinical Context Report

A Clinical Context Report Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and

More information

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

2014 DTC National Advertising Awards Finalists

2014 DTC National Advertising Awards Finalists 2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,

More information

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA

More information

Oncology Pipeline Analytics

Oncology Pipeline Analytics Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to

More information

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic

More information

Chapter / Section / Drug

Chapter / Section / Drug 2 Cardiovascular System 2.1 Positive inotropic drugs Digoxin Digoxin specific antibody ( DigiFab ) 2.2 Diuretics 2.2.1 Thiazides and related diuretics Indapamide (1 st Line) Bendroflumethiazide Metolazone

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA215; Pazopanib for the first line treatment of advanced

More information

Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial

Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,

More information

New Exception Status Benefits

New Exception Status Benefits AUGUST 2017 Nova Scotia Formulary Updates New Exception Status Benefits Forxiga (dapagliflozin) Xigduo (dapagliflozin and metformin hydrochloride) Criteria Update: Antipsychotic Medications Abilify (aripiprazole)

More information

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,

More information

Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada,

Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada, 1 Appendix Commentary 515 Appendix: Assessing Canada s Drug Shortage Problem Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada, 2013 16 Drug Name Dosage Therapeutic

More information

Spring How will that pipeline drug impact my benefit plan?

Spring How will that pipeline drug impact my benefit plan? Spring 2012 How will that pipeline drug impact my benefit plan? How will that pipeline drug impact my benefit plan? It can be difficult to predict the impact pipeline drugs will have once they reach the

More information

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,

More information

NICE TA Adherence Check List

NICE TA Adherence Check List NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs

More information

PRACTICAL MANAGEMENT OF NOAC s December 8,

PRACTICAL MANAGEMENT OF NOAC s December 8, PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation

More information

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude

More information

UP Health System Marquette Medication Guideline High Alert Drugs

UP Health System Marquette Medication Guideline High Alert Drugs 1 ALTEPLASE SOLR 100 MG ACTIVASE 305010 50242008527 TRUE ALTEPLASE SOLR 50 MG ACTIVASE 305008 50242004413 TRUE AMIODARONE INJ 50 MG/ML CORDARONE IV 305035 63323061609 TRUE AMIODARONE INJ 50 MG/ML CORDARONE

More information

JABLONSKI DEBATES PSA TESTING

JABLONSKI DEBATES PSA TESTING The JABLONSKI DEBATES PSA TESTING Getting Prostrate for the Prostate The JABLONSKI DEBATES Learning has never been this much fun (just like walking through a field littered with land mines.) The JABLONSKI

More information

Mifegymiso. New Exception Status Benefits

Mifegymiso. New Exception Status Benefits OCTOBER 2017 Nova Scotia Formulary Updates Mifegymiso New Exception Status Benefits Prozac (fluoxetine syr) Neupro (rotigotine) Brenzys (etanercept) Changes in Benefit Status Criteria Updates OAB Medications

More information

Critical Pathways in Breast Cancer Treatment

Critical Pathways in Breast Cancer Treatment Critical Pathways in Breast Cancer Treatment Faculty Jenny C Chang, MD Paul E Goss, MD, PhD Kathy D Miller, MD Lawrence N Shulman, MD Dennis J Slamon, MD, PhD Andrew Tutt, MB ChB, PhD Editor Neil Love,

More information

What s New in the AF Guidelines

What s New in the AF Guidelines Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What

More information

New Exception Status Benefits

New Exception Status Benefits AUGUST 2018 Nova Scotia Formulary Updates New Exception Status Benefits Ibrance (palbociclib) Erelzi (etanercept) Criteria Updates Ciprodex (dexamethasone and ciprofloxacin) Duloxetine (Cymbalta and generic

More information

GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst

GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: Age Edits Rx.01.2 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications

More information

A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)

A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015 J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,

More information

March 2017 P&T Updates

March 2017 P&T Updates March 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth DICLEGIS 3 No 2 No Yes EMVERM 2 No 2 Yes Yes Detailed s 4 tablets per day, 9 month supply per year Pinworms: 1 tablet

More information

NB Drug Plans Formulary Update

NB Drug Plans Formulary Update Bulletin # 914 October 14, 2015 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective October 14, 2015. Included in this bulletin: Special Authorization Benefit

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept

More information

Palliative Coverage Drug Benefit Supplement

Palliative Coverage Drug Benefit Supplement Palliative Coverage Drug Benefit Supplement Effective April 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases

Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300

More information

Alaska Medicaid 90 Day** Generic Prescription Medication List

Alaska Medicaid 90 Day** Generic Prescription Medication List 1 ACYCLOVIR 200 MG CAPSULE BUPROPION HCL 150 MG TAB ER 24H ACYCLOVIR 200 MG/5ML BUPROPION HCL 150 MG TABLET ER ACYCLOVIR 400 MG TABLET BUPROPION HCL 150 MG TABLET ER ACYCLOVIR 800 MG TABLET BUPROPION HCL

More information

Palliative Care Drug Benefit Supplement

Palliative Care Drug Benefit Supplement Palliative Care Drug Benefit Supplement Effective April 1, 2007 Inquiries Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number:

More information

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:

Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met: What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150 Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status

More information

THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER. HLC143A June Usha Nagavarapu Project Analyst ISBN: X

THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER. HLC143A June Usha Nagavarapu Project Analyst ISBN: X THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER HLC143A June 2013 Usha Nagavarapu Project Analyst ISBN: 1-56965-431-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

Engage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom

Engage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to

More information

Key ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism

Key ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism Key ASH Presentations Issue 5, 2012 SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology

More information

Pharmaceuticals and Medical Devices Safety Information

Pharmaceuticals and Medical Devices Safety Information Pharmaceuticals and Medical Devices Safety Information No. 248 July 2008 Table of Contents 1. Revision of PRECAUTIONS (No. 198) (1) Bepridil Hydrochloride (and 1 other) 3 2. List of products subject to

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA96; Adefovir dipivoxil and peginterferon alfa-2a for

More information

BENEFIT STATUS MFR PRODUCT STRENGTH DIN PRESCRIBER

BENEFIT STATUS MFR PRODUCT STRENGTH DIN PRESCRIBER DECEMBER 2018 Nova Scotia Formulary Updates Smoking Cessation Therapies New Exception Status Benefits Invega Trinza (paliperidone palmitate) Synjardy (empaglifozin/ metformin hydrochloride) Lancora (ivabradine

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018

Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Het CBG kan in schrijnende gevallen toestemming verlenen voor het in de handel brengen van een geneesmiddel

More information

Key ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)

Key ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL) Key ASH Presentations Issue 2, 2011 Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL) For more visit ResearchToPractice.com/5MJCASH2011 CME INFORMATION OVERVIEW OF ACTIVITY The annual

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ruperto N, Martini A. Current and future perspectives

More information

Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor

Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor TAKE CONTROL OF YOUR MIGRAINES! ABOUT THIS PATIENT GUIDE: Migraine attacks are often debilitating

More information

RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma

RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists

More information

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim) Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)

More information

Curriculum Vitae ARUN K. KALRA, MD

Curriculum Vitae ARUN K. KALRA, MD Curriculum Vitae ARUN K. KALRA, MD Office: CCARE California Cancer Associates in Research and Excellence 39755 Date St. Suite 103 Murrieta, California 92563 01/2017 to current. Arun Kalra MD Inc. 09/2016

More information

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:

More information

Comparison of Atypical Antipsychotics

Comparison of Atypical Antipsychotics PL Detail-Document #281006 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2012 Comparison of

More information

Recommended comparator products: Medicines for HIV/AIDS and related diseases

Recommended comparator products: Medicines for HIV/AIDS and related diseases Recommended comparator products: Medicines for HIV/AIDS and related diseases Comparator products should be purchased from a well regulated market with stringent regulatory authority 1. Invited medicinal

More information

PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6

PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6 Abiraterone Tablet 250 mg Q4 2016 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Available Alendronic Acid Tablet 70 mg Available Amikacin Solution for injection 50 mg/ml; 125mg/ml;

More information

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants) , fully signed Clinical Trial Agreements (except grants) Sponsor Full name of the Hospital clinic where the is details of the January x x January x NightstaRx Ltd A Randomised, Open Label, Outcomes-Assessor

More information

A Patient with Chest Pain and Atrial Fibrillation

A Patient with Chest Pain and Atrial Fibrillation A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)

More information

P.E.I. Drug Programs. Formulary Update. Issue June 09, 2010

P.E.I. Drug Programs. Formulary Update. Issue June 09, 2010 P.E.I. Drug Programs Formulary Update Issue 10-01 June 09, 2010 st Effective July 1, 2010, the following medications will be added to the P.E.I. Drug Formulary. New medications for the treatment of ankylosing

More information

The following are J Code requirements

The following are J Code requirements The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based

More information

Look-Alike/Sound-Alike (LASA) Medication Chart

Look-Alike/Sound-Alike (LASA) Medication Chart Look-Alike/Sound-Alike (LASA) Medication Chart Last Revised: August 2018 Lipid based amphotericin products amphotericin B lipid complex (Abelcet ) amphotericin B liposomal (Ambisome ) Conventional forms

More information

There are future perspectives in the pharmacological treatment of arrhythmias

There are future perspectives in the pharmacological treatment of arrhythmias There are future perspectives in the pharmacological treatment of arrhythmias George Andrikopoulos, MD, PhD, FESC, Cardiologist, Director, 1st Department of Cardiology/ Department of Electrophysiology

More information

Executive Summary. Reproduction prohibited v

Executive Summary.  Reproduction prohibited v Kinases are a large family of proteins that have now become firmly established as a major class of drug targets for the pharmaceutical industry. The sequencing of the Human Genome has led to the identification

More information

SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84

SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84 CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:

More information

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai. Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,

More information

University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2

University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2 2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS

More information

(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)

(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA) Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4

More information

NAME CTS AFFILIATION DISCLOSURE UPDATED

NAME CTS AFFILIATION DISCLOSURE UPDATED NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian

More information

ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.

ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1. ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882

More information

PPHP 2017 Formulary 2017 Step Therapy Criteria

PPHP 2017 Formulary 2017 Step Therapy Criteria ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)

More information

WHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.

WHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France. TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot

More information

Changes in Benefit Status and Criteria Update: Topiramate

Changes in Benefit Status and Criteria Update: Topiramate JANUARY 2016 Nova Scotia Formulary Updates Changes in Benefit Status and Criteria Update Topiramate Change in Benefit Status Escitalopram Criteria Update Actemra Januvia and Janumet Cimzia New Product

More information

ADVANCES IN MIGRAINE MANAGEMENT

ADVANCES IN MIGRAINE MANAGEMENT ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades

More information

Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5

Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5 Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo

More information

John Ansell President, John Ansell Consultancy Thame, UK

John Ansell President, John Ansell Consultancy Thame, UK Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1

More information

IRB INDICATION Number ENROLLED

IRB INDICATION Number ENROLLED Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA91: Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for the treatment of advanced ovarian

More information

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time

More information

ASCO 2011 Genitourinary Cancer

ASCO 2011 Genitourinary Cancer ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived

More information

Professionalism & Service with Great Prices

Professionalism & Service with Great Prices Acyclovir Capsules 200mg Viruses 30 90 Albuterol Syrup 2mg/5ml Asthma 120 360 Albuterol Sulfate Solution 0.05% * Asthma ----- ----- 20 60 Albuterol Sulfate Solution 0.083% Asthma ----- ----- 75 225 Alendronate

More information

CHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...

CHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)... CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...

More information

NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED)

NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED) HUMAN DRUGS NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 COMPANY BRAND NAME CHEMICAL NAME DIN THERAPEUTIC USE DATE OF FIRST SALE Abbott Laboratories Limited Norvir 100 mg/tablet ritonavir 02357593 HIV

More information

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide

More information

Drug Use Criteria: Direct Oral Anticoagulants

Drug Use Criteria: Direct Oral Anticoagulants Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed

More information

Getting ready for your shockwave lithotripsy (SWL)

Getting ready for your shockwave lithotripsy (SWL) Getting ready for your shockwave lithotripsy (SWL) Information for patients and families Your appointment is on: Check in time: Bring all medications that you are taking in their original containers and

More information